Thank you for sharing!

Your article was successfully shared with the contacts you provided.
While Myland says its discounts were consistent with federal guidance, the government says the company owed bigger discounts on EpiPen. (Photo: iStock)

Mylan NV has been overcharging the U.S. for years on its EpiPen allergy shot, a government agency said, as two lawmakers said the company was “bilking” taxpayers and may have made billions by misclassifying the drug under complex Medicaid pricing rules.


Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join BenefitsPRO.com now!

  • Unlimited access to BenefitsPRO.com - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
  • Exclusive discounts on BenefitsPRO.com and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2019 ALM Media Properties, LLC. All Rights Reserved.